Recursion announced that the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma. Recursion identified the novel regulatory role of RBM39 on CDK12 function using its AI-powered maps of biology. Recursion believes the modulation of RBM39 may be associated with a therapeutic effect in certain biomarker-enriched solid tumors and lymphoma. Preclinical data support that RBM39 degradation induces splicing defects which downregulate DNA Damage Response networks and cell cycle checkpoints.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Unusually active option classes on open December 2nd
- Cathie Wood’s ARK Investment buys 383K shares of Recursion Pharmaceuticals today
- Unusually active option classes on open November 20th
- Recursion Pharmaceuticals’ Strategic Acquisition and Leadership Changes
- Recursion, Exscientia officially combine to advance drug discovery